Combined immunohistochemistry of PRAME and p16 in the differentiation of melanocytic neoplasms, with a detailed focus on acral lesions

Diagn Pathol. 2024 Dec 27;19(1):167. doi: 10.1186/s13000-024-01586-y.

Abstract

Background: Isolated immunohistochemical indicators are limited to diagnose melanocytic neoplasms. This retrospective study is to assess the diagnostic value of combined immunohistochemical analysis targeting preferentially expressed antigen in melanoma (PRAME) and p16 in melanocytic neoplasms, with a detailed focus on arcal lesions.

Methods: This was a single center cohort study from January 2022 to June 2023. A total of 165 identified cases were collected, including 112 melanomas (MMs) and 53 melanocytic nevi, which were composed of 122 acral samples and 43 non-acral samples. Immunohistochemistry(IHC) for both PRAME and p16 was performed in these cases, which was subsequently statistically analyzed to assess the diagnosis ability of PRAME and p16.

Results: In total samples, the sensitivity and specificity of PRAME(+) for MM are 82.1% and 94.3% (AUC = 0.882, 95%CI:0.827-0.938), while of p16(-) for MM are 31.25% and 94.3% (AUC = 0.628, 95%CI:0.542-0.714); PRAME(+)/p16(-) (meaning as PRAME(+) or p16(-)) displayed a sensitivity and specificity of 85.7% and 88.7% for MM (AUC = 0.872, 95%CI:0.810-0.934), while PRAME(+) &p16(-) (meaning as PRAME(+) and p16(-)) revealed a sensitivity and specificity of 27.7% and 100% in MM (AUC = 0.638, 95%CI:0.555-0.722). In acral samples, PRAME(+)/p16(-) exhibited a specificity of 94.7% and a sensitivity of 86.9% for MM (AUC = 0.908, 95%CI: 0.849-0.968), with sensitivities of 90.9% for invasive MM and 82.5% for preinvasive MM, respectively; The sensitivity and specificity of PRAME(+) &p16(-) for MM is 22.6% and 100% (AUC = 0.613, 95%CI: 0.513-0.714) respectively. In non-acral samples, the sensitivity and specificity of PRAME(+)/p16(-) for MM are 82.1% and 73.3% (AUC = 0.777, 95%CI: 0.622-0.933), while of PRAME(+) &p16(-) are 42.9% and 100% (AUC = 0.714, 95%CI:0.564-0.864).

Conclusion: Combined IHC of PRAME and p16 contributes to discriminating melanocytic neoplasms, especially for in situ acral MM.

Keywords: Immunohistochemistry(IHC); Melanocytic nevus; Melanoma (MM); PRAME; p16.

MeSH terms

  • Adult
  • Aged
  • Antigens, Neoplasm* / analysis
  • Antigens, Neoplasm* / metabolism
  • Biomarkers, Tumor* / analysis
  • Cyclin-Dependent Kinase Inhibitor p16* / analysis
  • Cyclin-Dependent Kinase Inhibitor p16* / metabolism
  • Diagnosis, Differential
  • Female
  • Humans
  • Immunohistochemistry* / methods
  • Male
  • Melanoma* / diagnosis
  • Melanoma* / metabolism
  • Melanoma* / pathology
  • Middle Aged
  • Nevus, Pigmented* / diagnosis
  • Nevus, Pigmented* / metabolism
  • Nevus, Pigmented* / pathology
  • Retrospective Studies
  • Sensitivity and Specificity*
  • Skin Neoplasms* / diagnosis
  • Skin Neoplasms* / metabolism
  • Skin Neoplasms* / pathology
  • Young Adult

Substances

  • Antigens, Neoplasm
  • PRAME protein, human
  • Cyclin-Dependent Kinase Inhibitor p16
  • Biomarkers, Tumor
  • CDKN2A protein, human